Trial · NCT06285760
Registered outcomes24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 24
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in natriuresis 24 hours after acetazolamide | 24 hours | Change in natriuresis (mmol) 24 hours after acetazolamide association to medical treatment recommended by the guidelines (furosemide and ISGLT2). |
| Secondary | Increase in diuresis 24 hours after acetazolamide administration | 24 hours | Increase in diuresis 24 hours after acetazolamide administration (liters) |
| Secondary | Weight difference 24 hours after acetazolamide administration | 24 hours | Weight difference 24 hours after acetazolamide administration (Kg) |
| Secondary | Difference in congestion score 24 hours after acetazolamide administration. | 24 hours | Difference in congestion score 24 hours after acetazolamide administration using ADVOR congestion score. It is a 0-10 scale used in the ADVOR trial to objectively quantify volume overload in acute heart failure, based on three components: peripheral edema scored from 0 to 4 points, pleural effusion from 0 to 3 points, and ascites from 0 to 3 points. A total score of 0 represents the absence of measurable congestion, while the maximum of 10 indicates severe, multisite fluid accumulation. Higher ADVOR scores reflect more severe congestion. |
| Secondary | Difference in ultrasound measurement of Inferior Vena Cava 24 hours after acetazolamide administration. | 24 hours | Difference in inferior vena cava size (mm) assessed by ultrasound, he IVC is visualized in the subcostal long-axis view, and its diameter is measured about 1-2 cm from its junction with the right atrium, 24 hours after acetazolamide administration |
| Secondary | Change in natriuresis 48 hours after acetazolamide administration | 48 hours | Change in natriuresis 48 hours after acetazolamide administration |
| Secondary | Change in diuresis 48 hours after acetazolamide administration | 48 hours | Change in diuresis 48 hours after acetazolamide administration |
| Secondary | Weight difference 48 hours after acetazolamide administration | 48 hours | Weight difference 48 hours after acetazolamide administration |
| Secondary | Difference in congestion score 48 hours after acetazolamide administration. | 48 hours | Difference in congestion score 48 hours after acetazolamide administration using ADVOR congestion score. It is a 0-10 scale used in the ADVOR trial to objectively quantify volume overload in acute heart failure, based on three components: peripheral edema scored from 0 to 4 points, pleural effusion from 0 to 3 points, and ascites from 0 to 3 points. A total score of 0 represents the absence of measurable congestion, while the maximum of 10 indicates severe, multisite fluid accumulation. Higher ADVOR scores reflect more severe congestion. |
| Secondary | Difference in ultrasound measurement of Inferior Vena Cava 48 hours after acetazolamide administration. | 48 hours | Difference in inferior vena cava size (mm) assessed by ultrasound. The IVC is visualized in the subcostal long-axis view, and its diameter is measured about 1-2 cm from its junction with the right atrium, 48 hours after acetazolamide administration |
| Secondary | Change in Vexus score 24 hours after acetazolamide administration. | 24 h post acetazolamide administration | Vexus score: The VExUS score (Venous Excess Ultrasound Score) is an ultrasound-based grading system used to assess systemic venous congestion by integrating measurements of the inferior vena cava (IVC) and Doppler patterns of key abdominal veins: the hepatic vein, portal vein, and intrarenal vein. A dilated IVC combined with progressively abnormal venous Doppler waveforms indicates increasing venous congestion. VExUS is typically graded from 0 to 3, where Grade 0 represents no significant congestion and Grade 3 indicates severe venous congestion with markedly abnormal waveforms across multiple veins. Higher VExUS correlates with worse outcomes. |
| Other | Changes in renal function 24 hours after acetazolamide administration. | 24 hours | Changes in renal function assessed by differences in serum creatinine (mg/dL)24 hours after acetazolamide administration. |
| Other | Ionic (potassium (mmol/L) changes | 24 hours | Ionic (potassium (mmol/L) changes 24 hours after acetazolamide |
| Other | chloride (mmol/L) changes 24 hours after acetazolamide administration | 24 hours | chloride (mmol/L) changes 24 hours after acetazolamide |
| Other | bicarbonate (mmol/L) changes 24 hours after acetazolamide administration | 24 hours | bicarbonate (mmol/L) changes 24 hours after acetazolamide administration |
| Other | Changes in systolic blood pressure 24 hours after administration of acetazolamide | 24 hours | Changes in systolic blood pressure 24 hours after administration of acetazolamide (mmHg) |
| Other | Changes in renal function 48 hours after acetazolamide administration | 48 hours | Changes in renal function assessed by differences in serum creatinine (mg/dL) 48 hours after acetazolamide administration. |
| Other | Ionic (potassium (mmol/L) changes 48 hours after acetazolamide administration | 48 hours | Ionic (potassium (mmol/L) changes 48 hours after acetazolamide |
| Other | Chloride (mmol/L) changes 48 hours after acetazolamide administration | 48 hours | Chloride (mmol/L) changes 48 hours after acetazolamide |
| Other | Bicarbonate (mmol/L) changes 48 hours after acetazolamide administration | 48 hours | Bicarbonate (mmol/L) changes 48 hours after acetazolamide administration |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06285760/registered